Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03283787 · ClinicalTrials.gov registry record · NA

Comparing Concomitant Use of ACell MicroMatrix® and ACell Cytal™ to Standard of Care in Stage 3 or 4 Pressure Injuries

A NA study, sponsored by Integra LifeSciences Corporation.

Completed
Registry status
NA
Development phase
60
Enrollment target

NCT03283787: Completed NA study, sponsored by Integra LifeSciences Corporation.

NCT03283787 is a NA study that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03283787, a NA study, has completed, sponsored by Integra LifeSciences Corporation.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate incidence of complete epithelialization in stage 3 \& 4 pressure ulcers using ACell products.

Primary Outcome

Number of participant wounds with complete epithelialization by 12 weeks. Complete wound closure (epithelialization) determination based on PI assessment.

Interventions

  • DEVICE Negative Pressure Wound Therapy
  • DEVICE MicroMatrix® and Cytal™ Wound Matrix 2-Layer
  • DEVICE MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2017-04-01
Est. Completion 2019-12-23
Phase NA
Integra LifeSciences Corporation

60 total trials

What the finished NCT03283787 record still lists

NCT03283787 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 3 interventions - of which Negative Pressure Wound Therapy is the first listed.

NCT03283787 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03283787 about?

NCT03283787 is a clinical study titled "Comparing Concomitant Use of ACell MicroMatrix® and ACell Cytal™ to Standard of Care in Stage 3 or 4 Pressure Injuries". The purpose of this study is to evaluate incidence of complete epithelialization in stage 3 \& 4 pressure ulcers using ACell products.

What is the current status of trial NCT03283787?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2017-04-01. Estimated completion is 2019-12-23.

What interventions are being tested in trial NCT03283787?

The interventions under investigation include: Negative Pressure Wound Therapy (DEVICE), MicroMatrix® and Cytal™ Wound Matrix 2-Layer (DEVICE), MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT (DEVICE).

Who is sponsoring clinical trial NCT03283787?

This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03283787's enrollment target sits among peer trials

60 1164th of 2000 higher than 745 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03283787, the US trial registry maintained by the National Library of Medicine. NCT03283787 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.